Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients

(University of Pennsylvania School of Medicine) The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

In conclusion, LCMGUS represents a rela tively benign condition with a high disappearance rate of the monoclonal protein on longitudinal analysis and normal overall survival at least in the population-based setting.
Source: Annals of Hematology - Category: Hematology Source Type: research
ConclusionsReal-world data from US oncology practices indicate that many patients with multiple myeloma may not receive optimal therapy for bone disease, particularly those with renal impairment.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Authors: Richardson PG, Laubach J, Gandolfi S, Facon T, Weisel K, O'Gorman P Abstract INTRODUCTION: In multiple myeloma (MM), maintenance therapy is a longer and less intensive treatment course than initial therapy that is administered after induction to delay disease progression. Maintenance and continuous therapy have been shown to suppress minimal residual disease and deepen and prolong responses, with the goal of improving progression-free survival and overall survival. Areas covered: In this review, we have summarized current clinical trial data on maintenance and continuous therapy in newly-diagnosed MM and r...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Cancer Medicine, EarlyView.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Source Type: research
Cancer Medicine, EarlyView.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: Increased diffuse BM 18F-FDG uptake can be attributed to both bone marrow MI and benign etiologies. A decision tree based on C5.0 algorithm, combining PET/CT imaging and clinical features, is of potential use in discriminating BM malignant infiltration from patients with increased diffuse BM uptake.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Based on our earlier research into the main characteristics and risk factors for infections in hospitalized patients with multiple myeloma, we created the numerical Multiple Myeloma Index for Risk of Infection (MMIRI) to predict infection in myeloma patients. The included factors that could influence the pathogenesis and incidence of infections were sex, performance status, Durie Salmon stage of disease, International Staging System, serum creatinine level, immune paresis, neutropenia, serum ferritin level, the presence of any catheters, disease duration, stable/progressive disease, and type of therapy. For each of these p...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Short Research Communication Source Type: research
Multiple myeloma (MM) is a neoplastic plasma cell disorder with high disease recurrence rates. Novel therapeutic approaches capable of improving outcomes in patients with MM are urgently required. The AKT signalling plays a critical regulatory role in MM pathophysiology, including survival, proliferation, metabolism, and has emerged as a key therapeutic target. Here, we identified a novel AKT inhibitor, HS1793, and defined its mechanism of action and clinical significance in MM. HS1793 disrupted the interaction between AKT and heat shock protein 90, resulting in protein phosphatase 2A-modulated phosphorylated-AKT (p-AKT) reduction.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research
After enhancing the bioavailability of curcumin using polymers, a group of Washington State University researchers proved that curcumin can increase bone growth by between 30% and 45%  in a matter of weeks: “The presence of curcumin in TCP results in enhanced bone formation after 6 weeks.” (Quoted from the abstract.) The researchers are currently testing other natural extracts as well, namely “aloe vera, saffron, Vitamin D, garlic, oregano and ginger [… ] that might help with bone disorders, including those that encourage bone growth or that have anti-inflammatory, infection control, or a...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll bone building bone formation curcumin myeloma Source Type: blogs
sanifar Raymond Lai Malignant cells cultured in three-dimensional (3D) models have been found to be phenotypically and biochemically different from their counterparts cultured conventionally. Since most of these studies employed solid tumor types, how 3D culture affects multiple myeloma (MM) cells is not well understood. Here, we compared MM cells (U266 and RPMI8226) in a 3D culture model with those in conventional culture. While the conventionally cultured cells were present in single cells or small clusters, MM-3D cells grew in large spheroids. We discovered that STAT3 was the pathway that was more activated in 3D ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Heart | Myeloma | Toxicology | University of Pennsylvania